Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of subretinal CNTO 2476 in geographic atrophy secondary to age-related macular degeneration
jRCT1080223359Phase 2
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of palucorcel in age-related macular degeneration (AMD) (2 arms), sponsored by Janssen Pharmaceutical.
02
Drugs
palucorcel
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on jRCT1080223359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223359.